Exploring the Experimental and Computed Crystal Energy Landscape of Olanzapine
Source abstract
Abstract
An extensive experimental search for solid forms of the antipsychotic compound olanzapine identified 60 distinct solid forms including three nonsolvated polymorphs, 56 crystalline solvates, and an amorphous phase. XPac analysis of the 35 experimental crystal structures (30 from this work and 5 from the CSD) containing olanzapine show that they contain a specific, dispersion-bound, dimer structure which can adopt various arrangements and accommodate diverse solvents to produce structures with a similar moderate packing efficiency to form I. The crystal energy landscape confirms the inability of olanzapine to pack with an efficiency of more than 70%, explains the role of solvent in stabilizing the solvate structures, and identifies a hypothetical structural type that offers an explanation for the inability to obtain the metastable forms II and III separately. The calculations find that structures that do not contain the observed dimer are thermodynamically feasible, suggesting that kinetic effects are responsible for all the observed structures being based on the dimer. Thus, this extensive screen probably has not found all possible physical forms of olanzapine, and further form diversity could be targeted with a better understanding of the role of kinetics in its crystallization.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Crystallography and molecular interactions · Crystallization and Solubility Studies · X-ray Diffraction in Crystallography
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Solid-State Research Group, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, U.K.
Department of Chemistry, University College London, 20 Gordon Street, London WC1H 0AJ, U.K.
Eli Lilly and Company, Indianapolis, Indiana 46285, United States
References (65)
Show source-provided references
1. Price S. L. · Adv. Drug Delivery Rev. · 2004 · 56 · 30110.1016/j.addr.2003.10.006 ↗
2. Braga D. · Chem. Commun. · 2010 · 46 · 623210.1039/c0cc01195a ↗
3. Verwer P. · 2007 · 32710.1002/9780470125892.ch7 ↗
4. Day G. M. · Crystallogr. Rev. · 2011 · 17 · 310.1080/0889311X.2010.517526 ↗
5. Price S. L. · Acc. Chem. Res. · 2008 · 42 · 11710.1021/ar800147t ↗
6. Arlin J.-B. · Chem. Commun. · 2011 · 47 · 707410.1039/c1cc11634g ↗
7. Braun D. E. · Cryst. Growth Des. · 2010 · 11 · 21010.1021/cg101162a ↗
8. Braun D. E. · Cryst. Growth Des. · 2013 · 13 · 1910.1021/cg301506x ↗
9. Fulton B. · Drugs · 1997 · 53 · 28110.2165/00003495-199753020-00007 ↗
10. Tollefson G. D. · Am. J. Psychiatry · 1997 · 154 · 45710.1176/ajp.154.4.457 ↗
11. Sanger T. M. · J. Clin. Psychiatry · 2001 · 62 · 27310.4088/JCP.v62n0410 ↗
12. Allen F. · Acta Crystallogr., Sect. B: Struct. Sci · 2002 · 58 · 38010.1107/S0108768102003890 ↗
13. Reutzel-Edens S. M. · Cryst. Growth Des. · 2003 · 3 · 89710.1021/cg034055z ↗
14. Wawrzycka-Gorczyca I. · Acta Crystallogr. Sect. E: Struct. Rep. Online · 2004 · 60 · o6610.1107/S160053680302806X ↗
15. Thakuria R. · Acta Crystallogr., C · 2011 · 67 · o46110.1107/S0108270111043952 ↗
16. Wawrzycka-Gorczyca I. · J. Mol. Struct. · 2007 · 830 · 18810.1016/j.molstruc.2006.07.017 ↗
17. Polla G. I. · Int. J. Pharm. · 2005 · 301 · 3310.1016/j.ijpharm.2005.05.035 ↗
18. Capuano B. · Acta Crystallogr. Sect. E: Struct. Rep. Online · 2003 · 59 · o136710.1107/S1600536803017744 ↗
19. Wawrzycka-Gorczyca I. · Acta Crystallogr. Sect. E: Struct. Rep. Online · 2004 · 60 · o6910.1107/S1600536803028071 ↗
20. Salts have not been discussed further.
21. Sridhar B. · J Struct Chem · 2007 · 48 · 19810.1007/s10947-007-0032-x ↗
22. Ravikumar K. · Acta Crystallogr. E · 2005 · 61 · o272010.1107/S160053680502369X ↗
23. Thakuria R. · CrystEngComm · 2011 · 13 · 175910.1039/c0ce00787k ↗
24. Clarke H. D. · Cryst. Growth Des. · 2012 · 12 · 419410.1021/cg3007052 ↗
25. Tiwari M. · J. Pharm. Biomed. Anal. · 2007 · 43 · 86510.1016/j.jpba.2006.08.030 ↗
26. Bardwell D. A. · Acta Crystallogr., Sect. B: Struct. Sci · 2011 · 67 · 53510.1107/S0108768111042868 ↗
27. Kazantsev A. V. · Int. J. Pharm. · 2011 · 418 · 16810.1016/j.ijpharm.2011.03.058 ↗
28. Hulme A. T. · J. Am. Chem. Soc. · 2007 · 129 · 364910.1021/ja0687466 ↗
29. Gelbrich T. · CrystEngComm · 2005 · 7 · 32410.1039/b502484f ↗
30. Macrae C. F. · J. Appl. Crystallogr. · 2006 · 39 · 45310.1107/S002188980600731X ↗
31. Florence A. J. · J. Pharm. Sci. · 2003 · 92 · 193010.1002/jps.10459 ↗
32. Pawley G. · J. Appl. Crystallogr. · 1981 · 14 · 35710.1107/S0021889881009618 ↗
33. Rietveld H. · J. Appl. Crystallogr. · 1969 · 2 · 6510.1107/S0021889869006558 ↗
34. David W. I. F. · J. Appl. Crystallogr. · 2006 · 39 · 91010.1107/S0021889806042117 ↗
35. Coelho, A.TOPAS ACADEMIC, version 4.1;Coelho Software:Brisbane, 2007; pp1–131.
36. APEX2 User Manual, version 1.2.7;Bruker AXS Inc.:Madison, WI, 2005.
37. Sheldrick G. · Acta Crystallogr., Sect. A: Found. Crystallogr. · 2008 · 64 · 11210.1107/S0108767307043930 ↗
38. Farrugia L. · J. Appl. Crystallogr. · 1999 · 32 · 83710.1107/S0021889899006020 ↗
39. Spek A. · J. Appl. Crystallogr. · 2003 · 36 · 710.1107/S0021889802022112 ↗
40. Price S. L. · Phys. Chem. Chem. Phys. · 2010 · 12 · 847810.1039/c004164e ↗
41. Abraham R. J. · J. Chem. Soc., Perkin Trans. 2 · 1974 · 164810.1039/p29740001648 ↗
42. Karamertzanis† P. G. · Mol. Phys. · 2007 · 105 · 27310.1080/00268970601143317 ↗
43. Kazantsev A. V. · J. Chem. Theory Comput. · 2011 · 7 · 199810.1021/ct100597e ↗
44. Kazantsev A. V. · 2011 · 1
45. Cooper T. G. · J. Chem. Theory Comput. · 2008 · 4 · 179510.1021/ct800195g ↗
46. Cossi M. · J. Chem. Phys. · 2002 · 117 · 4310.1063/1.1480445 ↗
47. Gavezzotti A. · J. Phys. Chem. B · 2002 · 106 · 414510.1021/jp0144202 ↗
48. Gavezzotti A. · J. Phys. Chem. B · 2003 · 107 · 234410.1021/jp022288f ↗
49. Gavezzotti A. · CrystEngComm · 2003 · 5 · 43910.1039/b311836c ↗
50. Dunitz J. D. · Cryst. Growth Des. · 2005 · 5 · 218010.1021/cg050098z ↗
51. Chisholm J. A. · J. Appl. Crystallogr. · 2005 · 38 · 22810.1107/S0021889804027074 ↗
52. Gavezzotti A. · J. Am. Chem. Soc. · 1983 · 105 · 522010.1021/ja00354a007 ↗
53. Florence A. J. · J. Pharm. Sci. · 2006 · 95 · 191810.1002/jps.20647 ↗
54. Gelbrich T. · CrystEngComm · 2006 · 8 · 44910.1039/b600753h ↗
55. Tao J. · Cryst. Growth Des. · 2007 · 7 · 241010.1021/cg070387i ↗
56. Chen S. · J. Am. Chem. Soc. · 2005 · 127 · 1743910.1021/ja056072d ↗
57. Bond A. D. · Angew. Chem., Int. Ed. · 2007 · 46 · 61810.1002/anie.200603373 ↗
58. van de Streek J. · CrystEngComm · 2007 · 9 · 35010.1039/B615938A ↗
59. Price C. P. · Angew. Chem., Int. Ed. · 2006 · 118 · 211610.1002/ange.200503533 ↗
60. Parveen S. · Chem. Commun. · 2005 · 12 · 153110.1039/b418603f ↗
61. Billinge S. J. L. · CrystEngComm · 2010 · 12 · 136610.1039/B915453A ↗
62. Llinàs A. · Drug Discovery Today · 2008 · 13 · 19810.1016/j.drudis.2007.11.006 ↗
63. McKellar S. C. · ACS Comb. Sci. · 2012 · 14 · 15510.1021/co200175e ↗
64. Grzesiak A. L. · Angew. Chem., Int. Ed. · 2006 · 45 · 255310.1002/anie.200504312 ↗
65. Hiremath R. · J. Am. Chem. Soc. · 2005 · 127 · 1832110.1021/ja0565119 ↗